Vaccines

A new bill introduced by a group of senators aims to boost universal flu vaccine research by $1 billion over the next 5 years, as health officials continue to investigate the cause of the flu shot’s low efficacy.

A panel of experts in a recent symposium discuss how dental professionals can play an integral role in increasing HPV vaccination rates and decreasing HPV-related cancer.

The CDC’s Advisory Committee on Immunization Practices has included HEPLISAV-B on its list of recommended products for use to vaccinate adults against hepatitis B.

While a new report has found that the flu vaccine has been just 36% effective this year, a recent study suggests that history of exposure to flu may, in part, be to blame.

Massive vaccination campaigns launched in Brazil and Nigeria strive to quell ongoing outbreaks.

Providing investments in 10 vaccines during a 15-year period in low- and middle-income nations could prevent 36 million deaths and 24 million cases of poverty related to medical reasons.

Although rare, children inoculated against chicken pox can present with herpes zoster at or near the vaccination site.

A panel of experts from the Philippines Department of Health finds that Sanofi Pasteur's dengue fever vaccine, Dengvaxia (CYD-TDV), may be connected with 3 deaths.

Influenza A (H3N2) has caused most of the illnesses in this severe flu season, but influenza B is becoming increasingly responsible for more infections as the flu season continues to hit the United States.

A Nebraska mother’s Facebook post has parents and health experts around the country wondering if an influenza B infection may have caused hives in a child who did not present with any other flu symptoms.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

The CDC’s acting director provides a somber flu update and stresses the need to stay vigilant against the virus.

Despite a new report indicating that the flu vaccine hasn’t been very effective in North America this year, health officials say it’s still a valuable weapon against this severe flu season.

The vaccine candidate is ASP0113, which was in development to treat and prevent cytomegalovirus (CMV) in hematopoietic stem cell transplant recipients.

Findings from a new National Institutes of Health study may have important implications for flu vaccine development.

Richard Haupt, MD, MPH, explains why it’s harder to cover adults rather than children when it comes to vaccination.